钆塞酸二钠的临床安全性:基于20年使用及超过1200万次给药的经验
药物相关不良事件在III期和IV期研究中分别为6%和1.7%,未发现符合肾源性系统性纤维化的报告,美国放射学会已于2024年4月将其从III类重新分类为II类。
要点
- III期研究药物相关不良事件发生率6%,IV期1.7%;IV期相关严重不良事件9例(0.11%)。
- 美国放射学会于2024年4月将其肾源性系统性纤维化风险分类从III类改为II类。
核心结论
- 钆塞酸二钠在超过20年使用中表现出良好的安全性,未报告诊断或符合肾源性系统性纤维化的病例,美国放射学会据此于2024年4月将其从III类重新分类为II类。
诊断标准与关键数值
- 药物相关不良事件在III期研究为6%、IV期研究为1.7%;IV期相关严重不良事件9例(0.11%),III期无;I至III期最常见不良事件为恶心(1.4%)和头痛(1.2%),其余均≤1.0%;IV期最常见为呼吸困难(0.34%)和恶心(0.28%);药物警戒数据库最常见药物不良反应为过敏反应(报告率0.0147%)、恶心(0.0029%)和疼痛(0.0019%);给药量从2006年16578次增至2024年12月31日的每年1289979次,药物不良反应报告率从2006年0.21%降至2011至2024年的≤0.05%。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To comprehensively analyze worldwide safety data of gadoxetate disodium after 20 years of use and to review its reclassification from group III to group II on the American College of Radiology (ACR) nephrogenic systemic fibrosis (NSF)-risk classification scheme.
MATERIALS AND METHODS: Two safety data sets were analyzed: 23 clinical phase I to IV studies and Bayer pharmacovigilance database (PV) from 2004 to 2024. In addition, a literature review on NSF reports with special focus on patients with different degrees of renal impairment was performed. Patients' exposure was based on the assumption that one vial or prefilled syringe was given to each patient for each procedure, with an estimated total of over 12 million administrations. The primary target variable was the number, frequency and characteristics of unrelated/related adverse events (AEs) in clinical studies and adverse drug reactions (ADRs) reported to PV. Incidence and reporting rates were analyzed by descriptive statistical methods.
RESULTS: A total of 10,282 patients were included in clinical phase I to IV studies. Drug-related AEs were reported in 6% and 1.7% in phase III and IV studies, respectively. Nine (0.11%) related serious adverse events (SAEs) were recorded in phase IV, none in phase III. The most frequently recorded AEs (related or unrelated to drug) in phases I to III were nausea (1.4%) and headache (1.2%). All other AEs were reported ≤ 1.0%. In phase IV, dyspnea (0.34%) and nausea (0.28%) (related or unrelated) were most frequently reported. More than 12 million doses of gadoxetate were administered according to sales data. Most frequently reported ADRs from the PV were hypersensitivity reactions (reporting rate 0.0147%), nausea (0.0029%) and pain (0.0019%). Exposure increased steadily from 16,578 administrations in 2006 to 1,289,979 per year by December 31, 2024. Conversely, the ADR rate decreased from 0.21% in 2006 to ≤0.05% in 2011 through 2024. No report diagnostic of or consistent with NSF was documented, even in patients with renal impairment.
CONCLUSION: Liver-specific gadoxetate disodium demonstrated a favorable safety profile in patients independent of their renal function. No report diagnostic of or consistent with NSF has been reported with over 20 years of use. The well-established benefit/risk profile of gadoxetate disodium prompted the ACR to reclassify it from group III to group II as of April 2024.
引用
- Endrikat J, Bogosavljev B, Bhatti A, et al. Clinical Safety of Gadoxetate Disodium: Insights From 20 Years of Use and More Than 12 Million Administrations. Invest Radiol. 2026. PMID: 40662395. doi:10.1097/RLI.0000000000001224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。